1-3 of 3
John Fry
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A phase 1, multicenter, open-label, dose escalation study of elotuzumab in patients with advanced multiple myeloma

Clinical Trials & Observations
Jeffrey A. Zonder, Ann F. Mohrbacher, Seema Singhal, Frits van Rhee, William I. Bensinger, Han Ding, John Fry, Daniel E. H. Afar, Anil K. Singhal
Journal: Blood
Blood (2012) 120 (3): 552–559.
https://doi.org/10.1182/blood-2011-06-360552
Published: 2012
Journal Articles

Elotuzumab In Combination with Lenalidomide and Dexamethasone In Patients with Relapsed Multiple Myeloma: Interim Results of a Phase 2 Study

Paul G. Richardson, MD, Philippe Moreau, MD, Andrzej J Jakubowiak, MD, PhD, Thierry Facon, MD, Sundar Jagannath, MD, Ravi Vij, MD, Donna E Reece, MD, Darrell J White, MD, Marc S Raab, MD, PhD, Lotfi Benboubker, MD, PhD, Jean-Francois Rossi, MD, PhD, Claire Tsao, PhD, John Fry, David Berman, MD, PhD, Anil K Singhal, MD, Sagar Lonial, MD
Journal: Blood
Blood (2010) 116 (21): 986.
https://doi.org/10.1182/blood.V116.21.986.986
Published: 2010
Journal Articles

Phase 1/2 Study of Elotuzumab in Combination with Lenalidomide and Low Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma: Interim Results.

Sagar Lonial, Ravi Vij, Jean-Luc Harousseau, Thierry Facon, Jonathan Kaufman, Amitabha Mazumder, Philippe Moreau, Xavier Leleu, John Fry, Anil Singhal, Sundar Jagannath
Journal: Blood
Blood (2009) 114 (22): 432.
https://doi.org/10.1182/blood.V114.22.432.432
Published: 2009